{"url_path":"/sec/vyne/8-k/2026-05-21/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-065214-index.html","accession_number":"0001104659-26-065214","cik":"0001566044","ticker":"VYNE","issuer_name":"Yarrow Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-065214-index.html","primary_entity_key":"0001566044","primary_entity_name":"VYNE Therapeutics Inc."},"word_count":297,"has_tables":true,"body_markdown":"false\n0001566044\n\n0001566044\n\n2026-05-21\n2026-05-21\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the**\n\n**Securities Exchange Act of 1934**\n\n** **\n\n**Date of Report (Date of earliest event reported):\nMay 21, 2026**\n\n \n\n**VYNE\nTherapeutics Inc.**\n\n(Exact Name of Registrant as Specified in its\nCharter)\n\n \n\n**Delaware**\n \n**001-38356**\n \n**45-3757789**\n\n(State\nor Other Jurisdiction\n\nof Incorporation)\n\n \n\n(Commission\n\nFile Number)\n\n \n\n(IRS\nEmployer\n\nIdentification No.)\n\n \n\n \n \n \n\n**P.O. Box 125, Stewartsville, NJ**\n\n(Address of Principal Executive Offices)\n\n \n\n**08886**\n\n(Zip Code)\n\n \n\nRegistrant’s telephone number, including area code: (800) 775-7936\n\n \n\nCheck the appropriate box below if the Form 8-K filing\nis intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17\nCFR 240.14a-12)\n\n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under\nthe Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Trading\nsymbol(s)**\n \n\n**Name of each exchange**\n\n**on which registered**\n\n**Common\nStock, $0.0001 par value**\n \n**VYNE**\n \n**The Nasdaq Stock Market LLC**\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨"}